FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2031358049> ?p ?o ?g. }

• W2031358049 abstract "MEK and Aurora A kinase inhibitors (AAK) have profound impacts on cell cycle progression. Inhibition of MEK leads to defects in cell-cycle progression followed by cell cycle arrest and/or apoptosis. These cell-cycle progression defects may in part be due to the role of MEK in the DNA replication or damage checkpoint responses through positive regulation of DNA repair mechanisms. AAK inhibition leads to chromosome congression and segregation defects leading to DNA damage followed by apoptosis or senesence. The overlapping biological effects of inhibition of AAK and MEK kinases in cell cycle progression and chromosomal integrity raise the possibility that inhibiting both targets would provide added benefit over the inhibition of either target alone. The in vivo antitumor activity of TAK-733, an investigational potent, selective, non-ATP-competitive allosteric inhibitor of MEK, in combination with alisertib, an investigational potent, selective, reversible, ATP-competitive inhibitor of Aurora A kinase, was examined in experimental human solid tumor xenograft models including NSCLC (NCI H23 [KRAS and LKB1 mutations]), CRC (SW620 [KRAS, APC, p53 mutations]), and pancreatic cancer (Panc 1 and Capan 1 [KRAS mutations] and BxPC-3 [No MAPK mutations]) models in immunocompromised mice. The previously established maximally efficacious doses for the single agents dosed once daily (QD) orally (PO) (10 mg/kg TAK-733 and 30-mg/kg alisertib) were examined. A lower dose of 20 mg/kg alisertib was also examined in the event the maximally efficacious dose of each agent was not tolerated in combination. The once daily (QD) concurrent oral administration of TAK-733 and alisertib resulted in additive to synergistic antitumor activity and in prolonged inhibition of tumor regrowth after terminating treatment compared to single agent treatment in all xenograft models examined. Concurrent administration of TAK-733 and alisertib daily for 21 days was well tolerated. Treatment with TAK-733 alone and in combination with alisertib clearly inhibited phosphorylated ERK and produced a slight increase in phosphorylated histone H3. The results from the nonclinical models examined demonstrate considerable improvement in nonclinical antitumor activity over either single agent alone and provide a biological rationale for clinical evaluation of a TAK-733/alisertib combination in patients with advanced malignancies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3739. doi:1538-7445.AM2012-3739" @default.
• W2031358049 created "2016-06-24" @default.
• W2031358049 creator A5003610011 @default.
• W2031358049 creator A5007302063 @default.
• W2031358049 creator A5009944397 @default.
• W2031358049 creator A5029621607 @default.
• W2031358049 creator A5033379098 @default.
• W2031358049 creator A5047257123 @default.
• W2031358049 creator A5060733636 @default.
• W2031358049 creator A5065494091 @default.
• W2031358049 date "2012-04-15" @default.
• W2031358049 modified "2023-09-25" @default.
• W2031358049 title "Abstract 3739: TAK-733, an investigational, selective MEK1/2 inhibitor, in combination with alisertib (MLN8237), an investigational, selective Aurora A kinase inhibitor is tolerated and results in additive to synergistic antitumor activity: Results from In Vivo Studies" @default.
• W2031358049 doi "https://doi.org/10.1158/1538-7445.am2012-3739" @default.
• W2031358049 hasPublicationYear "2012" @default.
• W2031358049 type Work @default.
• W2031358049 sameAs 2031358049 @default.
• W2031358049 citedByCount "1" @default.
• W2031358049 countsByYear W20313580492016 @default.
• W2031358049 crossrefType "proceedings-article" @default.
• W2031358049 hasAuthorship W2031358049A5003610011 @default.
• W2031358049 hasAuthorship W2031358049A5007302063 @default.
• W2031358049 hasAuthorship W2031358049A5009944397 @default.
• W2031358049 hasAuthorship W2031358049A5029621607 @default.
• W2031358049 hasAuthorship W2031358049A5033379098 @default.
• W2031358049 hasAuthorship W2031358049A5047257123 @default.
• W2031358049 hasAuthorship W2031358049A5060733636 @default.
• W2031358049 hasAuthorship W2031358049A5065494091 @default.
• W2031358049 hasConcept C105696609 @default.
• W2031358049 hasConcept C121608353 @default.
• W2031358049 hasConcept C143425029 @default.
• W2031358049 hasConcept C184235292 @default.
• W2031358049 hasConcept C185592680 @default.
• W2031358049 hasConcept C190283241 @default.
• W2031358049 hasConcept C20552341 @default.
• W2031358049 hasConcept C2779425043 @default.
• W2031358049 hasConcept C2780808130 @default.
• W2031358049 hasConcept C2781187634 @default.
• W2031358049 hasConcept C2781249067 @default.
• W2031358049 hasConcept C29537977 @default.
• W2031358049 hasConcept C50001416 @default.
• W2031358049 hasConcept C502942594 @default.
• W2031358049 hasConcept C526805850 @default.
• W2031358049 hasConcept C54355233 @default.
• W2031358049 hasConcept C552990157 @default.
• W2031358049 hasConcept C55493867 @default.
• W2031358049 hasConcept C57074206 @default.
• W2031358049 hasConcept C86803240 @default.
• W2031358049 hasConcept C95444343 @default.
• W2031358049 hasConcept C98274493 @default.
• W2031358049 hasConceptScore W2031358049C105696609 @default.
• W2031358049 hasConceptScore W2031358049C121608353 @default.
• W2031358049 hasConceptScore W2031358049C143425029 @default.
• W2031358049 hasConceptScore W2031358049C184235292 @default.
• W2031358049 hasConceptScore W2031358049C185592680 @default.
• W2031358049 hasConceptScore W2031358049C190283241 @default.
• W2031358049 hasConceptScore W2031358049C20552341 @default.
• W2031358049 hasConceptScore W2031358049C2779425043 @default.
• W2031358049 hasConceptScore W2031358049C2780808130 @default.
• W2031358049 hasConceptScore W2031358049C2781187634 @default.
• W2031358049 hasConceptScore W2031358049C2781249067 @default.
• W2031358049 hasConceptScore W2031358049C29537977 @default.
• W2031358049 hasConceptScore W2031358049C50001416 @default.
• W2031358049 hasConceptScore W2031358049C502942594 @default.
• W2031358049 hasConceptScore W2031358049C526805850 @default.
• W2031358049 hasConceptScore W2031358049C54355233 @default.
• W2031358049 hasConceptScore W2031358049C552990157 @default.
• W2031358049 hasConceptScore W2031358049C55493867 @default.
• W2031358049 hasConceptScore W2031358049C57074206 @default.
• W2031358049 hasConceptScore W2031358049C86803240 @default.
• W2031358049 hasConceptScore W2031358049C95444343 @default.
• W2031358049 hasConceptScore W2031358049C98274493 @default.
• W2031358049 hasLocation W20313580491 @default.
• W2031358049 hasOpenAccess W2031358049 @default.
• W2031358049 hasPrimaryLocation W20313580491 @default.
• W2031358049 hasRelatedWork W1965478253 @default.
• W2031358049 hasRelatedWork W1970413166 @default.
• W2031358049 hasRelatedWork W1971658993 @default.
• W2031358049 hasRelatedWork W1983915589 @default.
• W2031358049 hasRelatedWork W2021166884 @default.
• W2031358049 hasRelatedWork W2027158543 @default.
• W2031358049 hasRelatedWork W2031945838 @default.
• W2031358049 hasRelatedWork W2067179863 @default.
• W2031358049 hasRelatedWork W2089396193 @default.
• W2031358049 hasRelatedWork W2089412634 @default.
• W2031358049 hasRelatedWork W2089553218 @default.
• W2031358049 hasRelatedWork W2166030259 @default.
• W2031358049 hasRelatedWork W2312667856 @default.
• W2031358049 hasRelatedWork W2318529741 @default.
• W2031358049 hasRelatedWork W2319328441 @default.
• W2031358049 hasRelatedWork W2560840299 @default.
• W2031358049 hasRelatedWork W2625442315 @default.
• W2031358049 hasRelatedWork W2786893289 @default.
• W2031358049 hasRelatedWork W2909946368 @default.
• W2031358049 hasRelatedWork W3095415073 @default.
• W2031358049 isParatext "false" @default.
• W2031358049 isRetracted "false" @default.
• W2031358049 magId "2031358049" @default.
• W2031358049 workType "article" @default.